Skip to main content
SpringerLink
Log in

Terapia con bisfosfonati o denosumab e osteonecrosi delle ossa mascellari

  • ENDOCRINOLOGIA E METABOLISMO OSSEO
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D (2017) Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo 69(1):9–15

    Article  CAS  PubMed  Google Scholar 

  2. English BC, Baum CE, Adelberg DE et al. (2010) A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 6:579–583

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Khan AA, Morrison A, Kendler DL et al. (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management fromthe international task force on ONJ. J Clin Densitom 20(1):8–24

    Article  PubMed  Google Scholar 

  4. Kuroshima S, Sasaki M, Nakajima K et al. (2018) Transplantation of noncultured stromal vascular fraction cells of adipose tissue ameliorates osteonecrosis of the jaw-like lesions in mice. J Bone Miner Res 33(1):154–166

    Article  CAS  PubMed  Google Scholar 

  5. Jung J, Yoo HY, Kim GT et al. (2017) Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner Res 32(12):2445–2452

    Article  CAS  PubMed  Google Scholar 

  6. Mauceri R, Panzarella V, Maniscalco L et al. (2018) Conservative surgical treatment of bisphosphonate-related osteonecrosis of the jaw with Er, Cr: YSGG laser and platelet-rich plasma: a longitudinal study. Biomed Res Int 2018:3982540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Sperimentale, Sezione di Fisiopatologia Medica, Endocrinologia e Scienza dell’Alimentazione, Università Sapienza, Roma, Italia

    Emanuela A. Greco

  2. Medicina Interna, Ospedale dell’Annunziata, Azienda Ospedaliera Cosenza, Cosenza, Italia

    Gianluca De Morelli

  3. Dipartimento di Scienze Umane, Motorie e della Salute, Sezione di Scienza della Salute, Università del Foro Italico, Roma, Italia

    Silvia Migliaccio

Authors
  1. Emanuela A. Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianluca De Morelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Migliaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuela A. Greco.

Ethics declarations

Conflitto di interesse

Gli autori, Emanuela A. Greco, Gianluca De Morelli e Silvia Migliaccio, dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greco, E.A., De Morelli, G. & Migliaccio, S. Terapia con bisfosfonati o denosumab e osteonecrosi delle ossa mascellari. L'Endocrinologo 20 (Suppl 1), 24–26 (2019). https://doi.org/10.1007/s40619-019-00546-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-019-00546-9

Search

Navigation